---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-027545"
form_type: "8-K"
ticker: "TRAW"
cik: "0001130598"
company_name: "Traws Pharma, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T05:31:09.058157+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Traws Pharma reports positive Phase 1 data for COVID-19 drug ratutrelvir; no ritonavir needed

## Summary
- Phase 1 data at 600 mg/day for 10 days show trough blood levels ~13x EC50 and >EC90 for 2 days post-treatment.
- Ratutrelvir suppressed 18 SARS-CoV-2 strains including nirmatrelvir-resistant and Omicron variants in lab tests.
- No requirement for ritonavir boosting due to favorable metabolism, potentially reducing drug-drug interaction risks.
- Excellent safety/tolerability in SAD and MAD studies at all doses tested; target Phase 2 dose defined.
- Company plans FDA interactions to initiate Phase 2; investor event March 31, 2025 at 10:00 AM ET.

## SEC filing metadata
- accession: 0001104659-25-027545
- form_type: 8-K
- ticker: TRAW
- cik: 0001130598
- company_name: Traws Pharma, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130598/000110465925027545/0001104659-25-027545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130598/000110465925027545/tm2510212d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-027545
- JSON: https://secwatch.observer/filing/0001104659-25-027545.json
- Plain text: https://secwatch.observer/filing/0001104659-25-027545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.